Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

734 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y; Lung Oncology Group in Kyushu, Japan. Ebi N, et al. Among authors: okamoto i. J Thorac Oncol. 2008 Oct;3(10):1166-71. doi: 10.1097/JTO.0b013e318186a88d. J Thorac Oncol. 2008. PMID: 18827614 Free article. Clinical Trial.
Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, Kinoshita T, Takeda M, Nakagawa K, Takamori S, Kuwano M, Ono M, Kage M. Azuma K, et al. Among authors: okamoto i. J Thorac Oncol. 2012 Jan;7(1):122-7. doi: 10.1097/JTO.0b013e31822eeba2. J Thorac Oncol. 2012. PMID: 21892099 Free article.
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K. Hasegawa Y, et al. Among authors: okamoto i. Invest New Drugs. 2013 Jun;31(3):599-604. doi: 10.1007/s10637-012-9833-7. Epub 2012 May 24. Invest New Drugs. 2013. PMID: 22623066 Clinical Trial.
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L).
Takeda M, Okamoto I, Yamanaka T, Nakagawa K, Nakanishi Y. Takeda M, et al. Among authors: okamoto i. BMC Cancer. 2012 Aug 1;12:327. doi: 10.1186/1471-2407-12-327. BMC Cancer. 2012. PMID: 22849580 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Kiyota H, Okamoto I, Takeda M, Daga H, Naito T, Miyazaki M, Okada H, Hayashi H, Tanaka K, Terashima M, Azuma K, Murakami H, Takeda K, Yamamoto N, Nakagawa K. Kiyota H, et al. Among authors: okamoto i. Cancer Chemother Pharmacol. 2013 Apr;71(4):859-65. doi: 10.1007/s00280-013-2077-1. Epub 2013 Jan 20. Cancer Chemother Pharmacol. 2013. PMID: 23334261 Clinical Trial.
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K. Okamoto I, et al. Oncotarget. 2014 Apr 30;5(8):2293-304. doi: 10.18632/oncotarget.1906. Oncotarget. 2014. PMID: 24810493 Free PMC article. Clinical Trial.
734 results